Revelation Biosciences, Inc.
REVB · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $4 | $10 | $11 | $101 |
| - Cash | $6 | $12 | $5 | $1 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$3 | -$2 | $6 | $99 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| EBITDA | -$8 | -$9 | -$11 | -$12 |
| % Margin | – | – | – | – |
| Net Income | -$15 | -$0 | -$11 | -$12 |
| % Margin | – | – | – | – |
| EPS Diluted | -87.68 | -8.41 | -9,643.37 | -20,400 |
| % Growth | -942.6% | 99.9% | 52.7% | – |
| Operating Cash Flow | -$18 | -$7 | -$11 | -$11 |
| Capital Expenditures | -$0 | $0 | $0 | -$0 |
| Free Cash Flow | -$18 | -$7 | -$11 | -$11 |